Clinical Trial: High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06812871) titled 'High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis' on Feb. 02.

Brief Summary: the study conducted to evaluate the efficacy and safety of high-dose furmonertinib (160 mg qd) combined with bevacizumab and pemetrexed intrathecal chemotherapy in NSCLC patients with EGFR mutations and meningeal metastases.

Study Start Date: Nov. 01, 2024

Study Type: INTERVENTIONAL

Condition: Non-small Cell Lung Cancer Metastatic

Intervention: DRUG: furmonertinib

furmonertinib (160mg, once a day, continuous administration); bevac...